Sigachi Industries Limited (NSEI:SIGACHI) is scouting for acquisitions of active pharmaceutical ingredient (API) manufacturing units, as it wants forward integration, the company top executive told ET. The company is in the process of raising INR 2.00 billion - INR 3.00 billion to fund the acquisitions. “We are actively looking out for (acquisition) opportunities in the API segment,” said Amit Raj Sinha, MD of Sigachi Industries in an interview to ET.

Sinha said the company is interested in acquiring the USFDA-compliant API manufacturing site, which gives them an immediate headstart to compete on an international level. Sigachi is considering various fund-raising options that include issuing equity or convertible warrants on a preferential basis to promoters, or possibly rights issue. Sinha added that the expansion into API segment, allows Sigachi to go beyond being just an excipient maker, into a more vertically integrated pharma company.

Sigachi is one of world's leading producers of microcrystalline cellulose (MCC) which is widely used as an excipient for finished oral solid and liquid dosages in the harmaceutical industry and has varied applications in the food, nutraceuticals and the cosmetics.